Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 31.
doi: 10.1007/s13346-025-01840-w. Online ahead of print.

Peptide-functionalized nanoparticles for brain-targeted therapeutics

Affiliations

Peptide-functionalized nanoparticles for brain-targeted therapeutics

Sophia Tang et al. Drug Deliv Transl Res. .

Abstract

Despite the rapid development of nanoparticle (NP)-based drug delivery systems, intravenous delivery of drugs to the brain remains a major challenge due to various biological barriers. To achieve therapeutic effects, NP-encapsulated drugs must avoid accumulation in off-target organs and selectively deliver to the brain, successfully cross the blood-brain barrier (BBB), and reach the target cells in the brain. Conjugating receptor-specific ligands to the surface of NPs is a promising technique for engineering NPs to overcome these barriers. Specifically, peptides as brain-targeting ligands have been of increasing interest given their ease of synthesis, low cytotoxicity, and strong affinity to target proteins. The success of peptides as targeting ligands is largely due to the diverse strategies of designing and modifying peptides with favorable properties, including membrane permeability and multi-receptor targeting. Here, we review the design and implementation of peptide-functionalized NP systems for neurological disease applications. We also explore advances in rational peptide design strategies for brain targeting, including using generative deep-learning models to computationally design new peptides.

Keywords: Blood–Brain Barrier; Drug Delivery; Nanoparticles; Peptides.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: No animal or human studies were carried out by the authors for this article. Consent for publication: No animal or human studies were carried out by the authors for this article. Competing interests: The authors have no relevant financial or non-financial interests to disclose.

Similar articles

Cited by

References

    1. Teixeira MI, Lopes CM, Amaral MH, Costa PC. Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): A current overview of active targeting in brain diseases. Colloids Surf B Biointerfaces. 2023;221:112999. https://doi.org/10.1016/j.colsurfb.2022.112999 . - DOI - PubMed
    1. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R. Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discov. 2021;20(2):101–24. https://doi.org/10.1038/s41573-020-0090-8 . - DOI - PubMed
    1. Kou L, Bhutia YD, Yao Q, He Z, Sun J, Ganapathy V. Transporter-Guided Delivery of Nanoparticles to Improve Drug Permeation across Cellular Barriers and Drug Exposure to Selective Cell Types. Front. Pharmacol. 2018;9, https://doi.org/10.3389/fphar.2018.00027 .
    1. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat Biotechnol. 2015;33(9):941–51. https://doi.org/10.1038/nbt.3330 . - DOI - PubMed - PMC
    1. Patra JK, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnology. 2018;16(1):71. https://doi.org/10.1186/s12951-018-0392-8 . - DOI - PubMed - PMC

LinkOut - more resources